GSK plc

GSK plc
Name	GSK plc
Type	Public limited company
Traded as	LSE: GSK, NYSE: GSK, FTSE 100 component
Foundation	2000; through merger of Glaxo Wellcome and SmithKline Beecham
Location	London, England, UK
Key people	Tony Wood (CEO), Jonathan Symonds (Chairman)
Industry	Pharmaceuticals
Products	Pharmaceuticals, Vaccines, Consumer healthcare

GSK plc. It is a global biopharmaceutical company headquartered in London, formed from the landmark merger of Glaxo Wellcome and SmithKline Beecham in 2000. The company operates across three core areas: pharmaceuticals, vaccines, and consumer healthcare, with a research focus on immunology, infectious diseases, and oncology. GSK is a constituent of the FTSE 100 Index and is listed on both the London Stock Exchange and the New York Stock Exchange.

History

The company's origins trace back to several historic entities, including a London pharmacy founded by John K. Smith and the Beecham Group established by Thomas Beecham. A major predecessor, Glaxo Laboratories, grew from a New Zealand infant food business. The modern corporation was created by the merger of Glaxo Wellcome—itself a product of the 1995 union of Glaxo and the Wellcome Foundation—with SmithKline Beecham in 2000, forming GlaxoSmithKline. In 2022, the company demerged its consumer healthcare business into the separate listed entity Haleon and rebranded as GSK plc. Key historical acquisitions include those of Block Drug and the vaccine businesses of Praxis Biologics and Sclavo.

Business segments

GSK's operations are divided into two primary commercial segments: Pharmaceuticals and Vaccines. The Pharmaceuticals segment focuses on developing and marketing medicines for diseases including HIV/AIDS, respiratory disease, and oncology, with key therapy areas in immunology and infectious diseases. The Vaccines segment is one of the world's largest, producing immunizations for conditions such as shingles, meningitis, and influenza. The former Consumer Healthcare segment, which included brands like Sensodyne and Panadol, was spun off to form the independent company Haleon in July 2022.

Products and research

The company's portfolio includes major pharmaceutical products such as the HIV drug dolutegravir, the severe asthma treatment mepolizumab, and the herpes zoster vaccine Shingrix. Its research and development is centered on four core therapeutic areas: infectious diseases, HIV, immunology, and oncology. GSK's R&D efforts utilize modalities like vaccine technology, small molecules, and monoclonal antibodies, with significant partnerships including those with Vir Biotechnology for COVID-19 treatments and the Bill & Melinda Gates Foundation for global health initiatives. Key research facilities are located in Stevenage, Upper Providence, and Cambridge.

Corporate affairs

The company's global headquarters are at GSK House in Brentford, London. It is led by Chief Executive Officer Tony Wood and chaired by Jonathan Symonds. GSK maintains a significant operational presence in the United States, with major sites in Philadelphia and Research Triangle Park. The company engages in numerous public–private partnerships for global health, such as with the World Health Organization and Gavi, the Vaccine Alliance. Its corporate structure was significantly altered by the 2022 demerger of Haleon, which was overseen by former CEO Emma Walmsley.

Financial performance

As a constituent of the FTSE 100, the company reports its financial results in Pound sterling. Its revenue is generated from global sales across its Pharmaceuticals and Vaccines segments, with the United States being its largest market. Major contributors to turnover include the vaccine Shingrix and the HIV portfolio. The demerger of Haleon involved a significant transfer of assets and was executed via a distribution to shareholders. Financial announcements and guidance are closely watched by analysts on the London Stock Exchange and New York Stock Exchange.

Controversies and legal issues

The company has faced significant legal challenges, including a $3 billion settlement with the United States Department of Justice in 2012 over allegations related to marketing practices for drugs like paroxetine and Avandia. It has also been involved in litigation concerning the cardiovascular risks of Avandia and patent disputes over its HIV medications. In China, a bribery scandal led to a fine from the Changsha Intermediate People's Court in 2014. The company has faced criticism and lawsuits related to its former consumer product Zantac, with plaintiffs alleging links to cancer.

Category:Pharmaceutical companies of the United Kingdom Category:Companies listed on the London Stock Exchange Category:FTSE 100 Index